Literature DB >> 31505252

Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.

Ahmed Nadeem1, Sheikh F Ahmad2, Naif O Al-Harbi2, Khalid E Ibrahim3, Nahid Siddiqui4, Mohammed M Al-Harbi2, Sabry M Attia2, Saleh A Bakheet2.   

Abstract

Asthma is a complex airways disease with a wide spectrum which ranges from eosinophilic (Th2 driven) to mixed granulocytic (Th2/Th17 driven) phenotypes. Mixed granulocytic asthma is a cause of concern as corticosteroids often fail to control this phenotype. Different kinases such as Brutons's tyrosine kinase (BTK) and IL-2 inducible T cell kinase (ITK) play a pivotal role in shaping allergic airway inflammation. Ibrutinib is primarily a BTK inhibitor, however it is reported to be an ITK inhibitor as well. In this study, we sought to determine the effect of Ibrutinib on Th1, Th17 and Th2 immune responses in a cockroach allergen extract (CE)-induced mixed granulocytic (eosinophilic and neutrophilic) mouse model in preventative mode. Ibrutinib attenuated neutrophilic inflammation at a much lower doses (25-75 μg/mouse) in CE-induced mixed granulocytic asthma whereas Th2/Th17 immune responses remained unaffected at these doses. However, at a much higher dose, i.e. 250 μg/mouse, Ibrutinib remarkably suppressed both Th17/Th2 and lymphocytic/neutrophilic/eosinophilic airway inflammation. At molecular level, Ibrutinib suppressed phosphorylation of BTK in neutrophils at lower doses and ITK in CD4 + T cells at higher doses in CE-treated mice. Further, effects of Ibrutinib were compared with dexamethasone on CE-induced mixed granulocytic asthma in therapeutic mode. Ibrutinib was able to control granulocytic inflammation along with Th2/Th17 immune response in therapeutic mode whereas dexamethasone limited only Th2/eosinophilic inflammation. Thus, Ibrutinib has the potential to suppress both Th17/Th2 and neutrophilic/eosinophilic inflammation during mixed granulocytic asthma and therefore may be pursued as alternative therapeutic option in difficult-to-treat asthma which is resistant to corticosteroids.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BTK; ITK; Ibrutinib; Mixed granulocytic asthma; Th2/Th17

Mesh:

Substances:

Year:  2019        PMID: 31505252     DOI: 10.1016/j.phrs.2019.104441

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  5 in total

Review 1.  Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.

Authors:  Ewa Robak; Tadeusz Robak
Journal:  J Clin Med       Date:  2022-05-16       Impact factor: 4.964

Review 2.  The Protective Effects of Helicobacter pylori Infection on Allergic Asthma.

Authors:  Zhi Tong Zuo; Ya Ma; Yan Sun; Cui Qing Bai; Chun Hua Ling; Feng Lai Yuan
Journal:  Int Arch Allergy Immunol       Date:  2020-10-20       Impact factor: 2.749

Review 3.  Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.

Authors:  Stefan F H Neys; Rudi W Hendriks; Odilia B J Corneth
Journal:  Front Cell Dev Biol       Date:  2021-06-04

Review 4.  Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis.

Authors:  Kristina S Lechner; Markus F Neurath; Benno Weigmann
Journal:  J Mol Med (Berl)       Date:  2020-08-18       Impact factor: 4.599

Review 5.  Targeting ITK signaling for T cell-mediated diseases.

Authors:  Samuel Weeks; Rebecca Harris; Mobin Karimi
Journal:  iScience       Date:  2021-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.